S trokes recur in ≈25% of patients in the first year, 1-4 with a 5-year cumulative recurrent risk of 30% to 40%. 5 Recurrent stroke leads to greater disability and case fatality. 6,7 The stroke recurrence rate has not changed over the past 20 years. 4 Evidence-based secondary stroke prevention guidelines improve stroke outcomes and reduce costs, 8 but remain underutilized. 9,10 Poor preventive care training, 11 discharge planning, 12,13 risk factor management, and communication with stroke patients/family 9 are likely contributors. 11, 14 Motivational interviewing (MI) aims to improve adherence to medication and lifestyle changes. MI facilitates intrinsic motivation to change behavior 15 and attempts to increase awareness of potential problems, consequences, and risks as a result of a behavior 16 and seeks to help people think differently about their behavior and consider potential gains through change. 17 MI is structured, patient-focused, 18-23 and more costeffective 24 than many other behavior change methods. 25,26 MI was developed for substance abuse management 21,22,27,28 but Background and Purpose-Stroke recurrence rates are high (20%-25%) and have not declined over past 3 decades. This study tested effectiveness of motivational interviewing (MI) for reducing stroke recurrence, measured by improving adherence to recommended medication and lifestyle changes compared with usual care. Methods-Single-blind, prospective phase III randomized controlled trial of 386 people with stroke assigned to either MI treatment (4 sessions at 28 days, 3, 6, and 9 months post stroke) or usual care; with outcomes assessed at 28 days, 3, 6, 9, and 12 months post stroke. Primary outcomes were change in systolic blood pressure and low-density lipoprotein cholesterol levels as indicators of adherence at 12 months. Secondary outcomes included self-reported adherence, new stroke, or coronary heart disease events (both fatal and nonfatal); quality of life (Short Form-36); and mood (Hospital Anxiety and Depression Scale). Results-MI did not significantly change measures of blood pressure (mean difference in change, −0.2.35 [95% confidence interval, −6.16 to 1.47]) or cholesterol (mean difference in change, −0.0.12 [95% confidence interval, −0.30 to 0.06]). However, it had positive effects on self-reported medication adherence at 6 months (1.979; 95% confidence interval, 0.98-3.98; P=0.0557) and 9 months (4.295; 95% confidence interval, 1.56-11.84; P=0.0049) post stroke. Improvement across other measures was also observed, but the differences between MI and usual care groups were not statistically significant. Conclusions-MI improved self-reported medication adherence. All other effects were nonsignificant, though in the direction of a treatment effect. Further study is required to determine whether MI leads to improvement in other important areas of functioning (eg, caregiver burden). Clinical Trial Registration-URL: http://www.anzctr.org.au. Unique identifier: ACTRN-12610000715077. The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/
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December 2015 is increasingly used in other populations, showing positive results in improving mood post stroke, [29] [30] [31] [32] [33] traumatic brain injury, 34 cardiovascular disease, 26, 35, 36 and diabetes mellitus. 37 This trial aimed to determine the effectiveness of MI in improving adherence to medications (particularly blood pressure [BP] and cholesterol lowering medications) in stroke patients enrolled into a larger population-based stroke study. Changes in systolic BP and low-density lipoprotein (LDL) cholesterol levels were assessed as primary outcomes. Other lipid fractions (high-density lipoprotein cholesterol, total cholesterol, triglycerides, and glycohemoglobin), self-reported adherence, occurrence of new stroke/coronary heart disease (fatal/nonfatal), changes in quality of life, and mood were also assessed.
Methods
Three hundred eighty-six people aged ≥16 years with stroke (excluding subarachnoid hemorrhage) were enrolled. The methodology is described in detail elsewhere, 38 but briefly, potential participants were identified by a hospital-based research assistant through checking hospital databases and attendance at weekly team meetings for relevant wards/units. Eligible candidates were approached in inpatient wards within 28 days of stroke. Medical notes of consenting individuals were reviewed and face-to-face screening conducted to explain the study and determine eligibility. Participants provided written informed consent. The study was approved by the regional ethics committee (NTX/10/09/091) and registered with Australian Clinical Trials Register (ACTRN-12610000715077).
Stroke was defined using World Health Organization diagnostic criteria. 39 Individuals were excluded if (1) they had impairment precluding participation (eg, aphasia, psychiatric conditions, cognitive impairment); (2) they were unable to converse in English; (3) they were unable to give informed consent; (4) they had another condition likely to affect participation (eg, significant aphasia); (5) they were receiving psychiatric/psychological treatment that could contaminate the findings; (6) they were discharged to hospital/nursing home setting where medications are given by staff; or (7) participation was likely to overburden the individual. Figure summarizes recruitment.
Participants were randomized to MI or usual care (UC). In accordance with New Zealand Clinical Guidelines for Stroke management, 41 individuals are admitted to specialized stroke care units within the public healthcare system, where services are provided by a designated stroke clinician. Ongoing inpatient rehabilitation occurs in a designated area under the care of an interdisciplinary team. After discharge, individuals are followed by their general practitioner or at a designated Stroke Clinic on a regular basis (eg, every 3 to 6 months). If further rehabilitation is required stroke-specific community-based rehabilitation teams are available. Regular reviews are recommended if residual impairment is present.
Treatment allocation was concealed from staff using an online randomization service. Stratified minimization randomization balanced for possible prognostic factors (ie, age [<70, 70+], sex, ethnicity [European, non-European], and Barthel Index [≤18, >18]) across the groups. 42 Randomization information was not accessible to staff conducting outcome assessments. After randomization, a letter was sent to participants' general practitioners to inform them of their patients' participation and remind them of recommendations to monitor BP and lipid levels post stroke. A letter was also sent to participants with a reminder to obtain BP and blood lipid levels from their general practitioner 12 months post stroke. A second reminder was sent with a blood lipid test form, 1 month before the 12-month assessment date.
Intervention
The MI group received 4 MI sessions at 28 days, 3, 6, and 9 months post stroke. Sessions were audio-recorded. The initial interview was conducted face-to-face either in hospital or in the participants' primary place of residence if he/she had been discharged. Subsequent interviews were conducted by telephone. If a telephone interview was not possible (eg, participant request, difficulty hearing), interviews were conducted face-to-face in the participants' primary place of residence. This occurred for 30%, 40%, and 21% of the 3-, 6-, and 9-month interviews, respectively. Initial interviews took 60 to 90 minutes, whereas follow-up sessions took ≈30 minutes. A manual describing the intervention in detail is provided (onlineonly Data Supplement). All MI sessions were administered by trained researchers under the supervision of an MI trainer, who also provided ongoing training and feedback throughout the study to ensure the fidelity of the intervention. Participants were assigned 1 MI interviewer, who remained consistent across the study whenever possible.
Measures
Assessments were conducted 28 days, 3, 6, 9, and 12 months post stroke over the telephone by trained researchers, who were blind to randomization status and were not involved in providing the MI intervention.
Primary outcomes were change in systolic BP and LDL cholesterol levels from baseline to 12 months post randomization. Secondary outcomes were new cardiovascular events (eg, presence/absence of further stroke, myocardial infarction), quality of life (Short Form-36 42 ), change in other lipid fractions (high-density lipoprotein cholesterol and total cholesterol), and change in mood (Hospital Anxiety and Depression Scale 43 ), and medication adherence. Medication adherence was determined by asking whether (in the past 7 days) they had taken all of their medication as prescribed; for each medication, they were asked to indicate number of doses/pills missed; if they just forgot (yes/no), the reason for the missed dose(s); and to provide detail if side effects were noted. The validity of self-reports of adherence was cross-checked with electronic medication dispense records, where available. To not unduly bias reporting of adherence, every attempt was made to ensure that measures of adherence conducted at 28 days, 3, 6, and 9 months preceded MI sessions. Measures were completed before MI sessions for 66% to 84% of participants across the 4 assessments.
The Short Form-36 42 assesses health-related quality of life. It has been validated in New Zealand 44 45 Disability was assessed using the Barthel Index, which assesses ability to perform ten activities of daily living associated with personal care (eg, feeding) and mobility (eg, transfers). The Barthel Index can be self-administered or completed by a clinician, taking 5 to 10 minutes. The maximum score (20) indicates full independence.
Analyses
Analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC). All tests were 2-sided with a 5% level of significance. With a sample of 364 stroke patients (including 20% drop-outs), this trial had 90% power to detect 20% improvement in adherence to lipid-lowering or antithrombotic medications. Only 302 stroke patients (20% drop-outs; 90% power) were required to detect 20% improvement in adherence to BP-lowering medications.
Baseline demographic/clinical characteristics of all randomized participants were summarized using descriptive statistics, and baseline imbalance was tested between UC and MI groups. Unadjusted relative risks were first calculated on self-reported adherence and cardiovascular events. Generalized linear regression models were then conducted to estimate treatment differences on primary and secondary outcomes, adjusting for baseline outcome and stratification factors prespecified as a standard approach suggested by ICH guidelines. 46 Random effects mixed models were used to assess outcomes measured over time, taking into account repeated measurement on the same participant. Model adjusted mean differences and odds ratios were estimated for continuous and binary outcomes, respectively, with associated 95% confidence intervals and P values. Treatment evaluations were performed on the principle of intention-to-treat. Missing data on the primary outcome were imputed using the lastvalue-carry-forward approach. Sensitivity analysis was conducted on observed data to evaluate the robustness of main trial results. No imputation was considered on secondary outcomes, and there was no adjustment on multiple testing. Tabulated data are consistent with CONSORT 2010 guidelines. 47 Results Table 1 provides descriptive information for MI and UC groups. Randomization achieved good balance between the groups. Both groups were prescribed medications at similar rates over time (Table 2) , and self-reported adherence was high (>85%) in both groups at each time point ( Table 3) .
The groups did not differ significantly in reporting of side effects at any of the assessments (P>0.05), although more of those in the UC group (n=12, 6.2%) reported forgetting to take medications than in the MI group (n=4, 2.1%) at 9 months (P=0.042). Of the 26 individuals, who reported other reasons for not adhering, 11 (44%) did not wish to take medication, 8 (32%) indicated their prescription ran out, 2 (8%) said they were unaware of the prescription, 2 (8%) said taking medication was inconvenient, and 3 (12%) stated a preference for naturopathic alternatives, changed their dose to see how they would do, or that it was expensive. The groups did not differ significantly in reporting these barriers (P>0.05).
There was a significant treatment effect for self-reported adherence at 9 months and this approached significance at 6 months.
There was no difference in the number of cardiovascular events in the MI and UC groups over 12 months (<7%; Table 3 ). The reduction in systolic BP in both groups was large (>15 mm Hg) and clinically and statistically significant but there were no statistically significant differences between the groups (Table 4) , and the direction of change is in the direction expected for a treatment effect. LDL cholesterol levels did not differ between or within the groups from baseline to 12 months. BP, lipid profile, mood, and quality of life measures did not change across the intervention period (Table 5) , with no effect of treatment.
Discussion
Although MI did not significantly improve performance on the primary outcomes (ie, systolic BP, LDL cholesterol), it did have a favorable effect on self-reported medication adherence after incident stroke. MI also resulted in a trend for improvement across other measures related to adherence (eg, systolic BP), although these effects were not statistically significant. 
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The effect of MI on medication adherence neared significance at 6 months and reached significance at 9 months, which likely reflects the timing of the final MI session. MI aims to improve adherence through increasing participant motivation, and it was hoped that improved adherence would be associated with improved broader outcomes. There was a trend toward better overall recovery in the MI group, but the study was not adequately powered to detect a clinically relevant difference in cardiovascular outcomes and the 12-month follow-up period may have been too short for changes in adherence to affect more distant outcomes.
Previous MI studies have shown significant reductions in depressed mood and mortality 12 months post stroke. 48 In this study, depression and anxiety were both reduced over time, but this did not differ between the groups. This may be because of the timing and intensity of the intervention, as we provided 3 MI sessions spaced over 9 months. An earlier study 48 provided weekly sessions for ≤4 weeks beginning within 4 weeks post stroke. Other studies post stroke have not examined talk-based therapies delivered so early poststroke nor found such benefits. 49 Together, the findings suggest that MI enhances adaptive behavioral changes post stroke (such as medication adherence) and suggests further research is warranted regarding frequency and timing of MI sessions. Detailed comparison of the current trial with others is difficult as previous trials predominantly focus on different population groups. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The strengths of the study are that it was the first full-scale randomized controlled trial to evaluate the impact of MI on adherence and cardiovascular consequences of adherence in stroke survivors; it had a large sample statistically powered to identify change in the primary outcome; it had a low attrition rate, and missing data were low. The main limitations were (1) the strict inclusion criteria may limit generalizability; (2) use of imputation using last-value-carried-forward, while a sound approach, may have reduced ability to detect statistically significant changes in primary outcomes as values were carried forward in 16% of cases for systolic BP and as much as 38% for LDL, and (3) because of the nature of MI, it was not possible to blind participants which may have influenced selfreport outcomes. Although medication adherence measured by self-report is simple and inexpensive and is validated for use in clinical settings, it may have led to overestimation of adherence. 49, 50 Provision of a specified timeframe (the past 7 days) and including questions about specific behavior (eg, number of pills missed) are known to have improved self-report accuracy in this context. 51, 52 As noted in the Methods section, validity of self-reports was cross-checked with electronic medication dispense records where available, which suggests accurate reporting. Long-term sustainability of the treatment effect beyond 12 months post randomization requires evaluation.
Notwithstanding these limitations, MI had a positive effect on self-reported adherence suggesting it may be beneficial. Whether this intervention is cost-effective and leads to improvement in other important areas of functioning (eg, caregiver burden) and whether its positive effects are maintained long-term should be a subject of further research in an adequately powered study with sufficient follow-up in order to accrue enough clinical events.
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Motivational Interviewing Intervention Manual
MIST Study 
Intervention Protocol
1. Ensure that interviewer has completed basic motivational training including shadowing at least two interviews.
2. One day prior to interviews a. Contact the client to confirm the interview day and time. If any observers will be part of the interview ask for the client's permission at this time. b. Ensure the interview date, time and location is in the interviewer's Outlook calendar so that study managers know where you are. Include study participant ID, initials and address in location field so manager can see these details. NOTE: Ensure your outlook calendar is viewable to everyone. c. Find a work colleague to be your "buddy" to text before you go into the interview and when you leave the interview. If you cannot find a "buddy" then Emma and/or Amy can be back-up contacts.
3. On the day of the interview a. Review the client case notes to refresh pertinent information b. Check recording equipment and ensure that there are spare batteries c. Plan on arriving 15 minutes early d. Text message or let your buddy or a manager know in person that you are going to an appointment. Make an arrangement for how you will notify them when you have finished the appointment, e.g. send a text or see in office. e. Remove any distractions. Put mobile phone on silent if a face-to-face interview. If a phone interview move away from the computer and/or any clutter. For telephone interviews book a private meeting room with a speaker phone (e.g. room AA123, AA256 or AA203) when the appointment time is made. To book a room contact George Palmer on gpalmer@aut.ac.nz or extension 9005. f. Ground yourself 5-10 minutes prior to the start of the interview. Practice your mindfulness ritual 4. Start the interview a. Re-introduce yourself by name and job title and show your AUT id, if a face-toface meeting b. Observe any cultural practices, such as removing shoes in the house, when doing interviews c. Remind the client that the interview will be recorded and that colleagues working on the study may listen in for training purposes. If there are any observers at this point confirm permission from the client for the observer to listen in. d. Remind the client that motivational interviewing is most effective when they are not distracted by other things such as people, computers, or phones. e. Take notes as needed. f. If, at any time, you feel unsafe or that the interview is unsafe for the client, you can end the interview. Depending on the extent of the concern, you can wrap-up and follow-up later or leave urgently. i. Examples of red flags for clients include moderate to severe depressive symptoms, suicide and/or self-harming. Report these signs to a program manager after an interview so appropriate actions may be taken. what could be improved, e .g "At our next interview, is there anything I can do different?", or "How can I best support you?". e. Remind participant of the timing of the next interview and let them know you will call to confirm closer to the date. f. Thank them for participating and for the willingness to share. g. Stop the recording. Of all the people who agree to participate in the study, half will receive motivational interviewing and the other half will not. You have been selected for the group that receives motivational interviewing. It's really important that the other people from our team do not know which patients are receiving the motivational interviews. Is that ok? (NOTE: Give the name of the Form T assessor if possible.)
Motivational Interviewing is a style of intervention that is designed to help build a person's motivation to change. It will probably just feel like a conversation where we will explore things together. I am not a health expert and I will not be telling you what to do but I am training in how to help you explore your own health and wellbeing and what areas you may want to improve to prevent stroke.
It is most effective when you are undistracted by other people, television, computers, etc. Please plan to find a quiet place where you can be alone and focus on yourself.
There will be four motivational interviews over the course of 12 months. I will be doing your first motivational interview soon and I will contact you again in 3 months, 6 months and 9 months time to arrange further interviews. The first interview will be face-to-face and the following interviews can be done over the telephone if this is suitable for you.
Intervention Protocol: First Interview
1. Follow all "Interview Protocol" listed previously a. Remember to reintroduce yourself by name and job title. Show your photo id if at a face-to-face meeting. b. Try to avoid acronyms such as AUT or MIST. Use the full word. c. Wrap-up with a summary and get client input on how the interview went.
2. Explain that you are here for the first motivational interview and that the appointment will take about one hour.
3. Encourage them to minimize any distractions now, if they need too.
4.
Remind the study participant that the interviews are recorded and begin recording. If the participant does not wish the interview to be recorded, explain that the main purpose of the recording is to make sure that you are following intervention guidelines, the recording is anonymous and stored securely. The recording may be listened to by your trainer and immediate research colleagues for training and assessment purposes only.
5.
Review the purpose of the study ('Setting the stage') a. For example you might say, "Today we will use a technique called motivational interviewing to discuss how the different areas of your wellbeing, such as physical and mental health, impact your life and your ability to prevent a second stroke." 2. Explain that you are here for the follow-up motivational interview and that the appointment will take about half an hour.
3. Encourage them to minimize any distractions now, if they need to.
4. Remind them that the interviews are recorded and begin recording.
Thank them for their time and honor their commitment to improving their own health by participating in the motivational interviewing intervention.
6. The second and third interviews are an opportunity to use the values, dreams and vision of the client that you gained in the first interview to apply to motivating change and commitment to goals.
7. Begin with a broad, positive question such as "Can you share with me something positive that has happened since we last spoke?" a. Note: You do not start by reviewing the last conversation. Begin broad and on a positive focusing for example on values, dreaming or goals b. If the client moves toward negative topics, try to draw back to a positive, e.g. "It sounds like you've had a hard time, has any good come from that?" 8. Explore with clients what areas in their life they would like to improve and facilitate their commitment to make healthy change. Ideas on how to motivate change include: a. Use positive reinforcement for any changes made or any change talk expressed. Also acknowledge any progress towards recovery and ask how the participant feels about these. b. Ask what the broader benefits of change have been and any negatives they have identified. Reinforce any coping skills used in dealing with these and also acknowledge determination. c. Ask what has gone well with their plans and what has gone less well. Express empathy and ask questions that allow for problem-solving s and future planning. d. Ask how important they feel the changes are now and again how confident they are that they can make these changes -use scales if needed. e. Acknowledge any reduction in motivation or confidence since the last interview and explore why this is. Also encourage the participant to identify what would need to change in the future for motivation and confidence to increase.
f. Recognize ambivalence as a normal part of change and ask questions that highlight discrepancies or strengthen commitment to change. Do this in a motivational way.
Intervention Protocol: Follow-Up Interviews Continued
g. Ask the participant whether they have any new changes they want to make. Ask what these changes would look like and how it would feel. Allow space for the participant to consider any potential barriers and how they might manage these. h. Ask the participant to look back and identify any strengths or skills they have used in the past which may transferable to current issues. i. If a client is ready to commit to change, set one to five SMART goals with the client. Ensure that the goals are: i. Specific ii. Measurable iii. Attainable iv. Realistic v. Timely j. Only give advice or information if the participant is open to this and you have asked for permission. One opportunity to share ideas with clients would be in a brainstorming session.
Motivational Interviewing Techniques: Open-Ended Questions Continued
8. Sample open-ended questions below. NOTE: These are not in any particular order and it would not likely be appropriate to ask them all in one interview. 
